In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors

Journal of Clinical Investigation

Volumn 101, Issue 8, 1998, Pages 1789-1796

  Kojima, Akira ^a   Hackett, Neil R ^a   Ohwada, Akihiko ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Camptothecins; Carboxylesterase; Gene therapy; Lung cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; IRINOTECAN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; INTRATUMORAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0032523096     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119888     Document Type: Article

References (46)

1. Fukuoka, M., H. Niitani, A. Suzuki, M. Motomiya, K. Hasegawa, Y. Nishiwaki, T. Kuriyama, Y. Ariyoshi, S. Negoro, N. Masuda, et al. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10:16-20.
2. Masuda, N., M. Fukuoka, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, S. Negoro, M. Nishioka, K. Nakagawa, and M. Takada. 1992. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1225-1229.
3. Ohno, R., K. Okada, T. Masaoka, A. Kuramoto, T. Arima, Y. Yoshida, H. Ariyoshi, M. Ichimaru, Y. Sakai, M. Oguro, et al. 1990. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1907-1912.
4. Shimada, Y., M. Yoshino, A. Wakui, I. Nakao, K. Futatsuki, Y. Sakata, M. Kambe, T. Taguchi, N. Ogawa, and The CPT-11 Gastrointestinal Cancer Study Group. 1993. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11:909-913.
5. Takeuchi, S., H. Takamizawa, Y. Takeda, T. Ohkawa, T. Tamaya, K. Noda, T. Sugawa, K. Sekiba, M. Yakushiji, and T. Taguchi. 1991. An early phase II study of CPT-11 in gynecologic cancers. Research group of CPT-11 in gynecologic cancers. Gan. To. Kagaku. Ryoho. 18:579-584.
6. Kunimoto, T., K. Nitta, T. Tanaka, N. Uehara, H. Baba, M. Takeuchi, T. Yokokura, S. Sawada, T. Miyasaka, and M. Mutai. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:5944-5947.
7. Kawato, Y., M. Aonuma, Y. Hirota, H. Kuga, and K. Sato. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:4187-4191.
8. Kaneda, N., H. Nagata, T. Furuta, and T. Yokokura. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1715-1720.
9. Lavelle, F., M.C. Bissery, S. Andre, F. Roquet, and J.F. Riou. 1996. Pre-clinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol. 23: 11-20.
10. Negoro, S., M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, H. Niitani, and T. Taguchi. 1991. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer. Inst. 83: 1164-1168.
11. Ohe, Y., Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, A. Kojima, H. Kunikane, H. Okamoto, A. Karato, H. Ohmatsu, et al. 1992. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer. Inst. 84:972-974.
12. Hersh, J., R.G. Crystal, and B. Bewig. 1995. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2:124-131.
13. Kroetz, D.L., O.W. McBride, and F.J. Gonzalez. 1993. Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry. 32:11606-11617.
14. Korst, R.J., B. Bewig, and R.G. Crystal. 1995. In vitro and in vivo transfer and expression of human surfactant SP-A-and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum. Gene Ther. 6:277-287.
15. McGrory, W.J., D.S. Bautista, and F.L. Graham. 1988. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 163:614-617.
16. Ohwada, A., S. Rafii, M.A. Moore, and R.G. Crystal. 1996. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Blood. 88:778-784.
17. Ohwada, A., E.A. Hirschowitz, and R.G. Crystal. 1996. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocylosine to suppress the growth of colon carcinoma metastatic to liver. Hum. Gene Ther. 7:1567-1576.
18. Rosenfeld, M.A., K. Yoshimura, B.C. Trapnell, K. Yoneyama, E.R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L.E. Stier, L. Stratford-Perricaudet, et al. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 68:143-155.
19. Thomas, P.S. 1980. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA. 77:5201-5205.
20. Mertz, L.M., and A. Rashtchian. 1994. Nucleotide imbalance and polymerase chain reaction: effects on DNA amplification and synthesis of high specific activity radiolabeled DNA probes. Anal. Biochem. 221:160-165.
21. Krisch, K. 1966. Reaction of a microsomal esterase from hog-liver with diethyl p-nitrophenyl phosphate. Biochim. Biophys. Acta. 122:265-280.
22. Barilero, I., D. Gandia, J.P. Armand, A. Mathieu-Boue, M. Re, A. Gouyette, and G.G. Chabot. 1992. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. 575:275-280.
23. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55-63.
24. Hirschowitz, E.A., A. Ohwada, W.R. Pascal, T.J. Russi, and R.G. Crystal. 1995. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther. 6:1055-1063.
25. Danks, M.K., C.L. Morton, C.A. Pawlik, and P.M. Potter. 1998. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res. 58:20-22.
26. Munger, J.S., G.P. Shi, E.A. Mark, D.T. Chin. C. Gerard, and H.A. Chapman. 1991. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J. Biol. Chem. 266:18832-18838.
27. Shibata, F., Y. Takagi, M. Kitajima, T. Kuroda, and T. Omura. 1993. Molecular cloning and characterization of a human carboxylesterase gene. Genomics. 17:76-82.
28. Tsuruo, T., T. Matsuzaki, M. Matsushita, H. Saito, and T. Yokokura. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:71-74.
29. Armand, J.P., M. Ducreux, M. Mahjoubi, D. Abigerges, R. Bugat, G. Chabot, P. Herait, M. de Forni, and P. Rougier. 1995. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer. 31A:1283-1287.
30. Rothenberg, M.L., J.R. Eckardt, J.G. Kuhn, H.A. Burris III, J. Nelson, S.G. Hilsenbeck, G.I. Rodriguez, A.M. Thurman, L.S. Smith, S.G. Eckhardt, et al. 1996. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. 14:1128-1135.
31. Kojima, A., T. Shinkai, and N. Saijo. 1993. Cytogenetic effects of CPT-11 and its active metabolite. SN-38 on human lymphocytes. Jpn. J. Clin. Oncol. 23:116-122.
32. Gutierrez, A.A., N.R. Lemoine, and K. Sikora. 1942. Gene therapy for cancer. Lancet. 339:715-721.
33. Moolten, F.L. 1994. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:279-287.
34. Then, S.H., H.D. Shine, J.C. Goodman, R.G. Grossman, and S.L.C. Woo. 1994. Gene therapy for brain tumors: regression of experimental gliomas by adenovinis-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 91: 3054-3057.
35. Culver, K.W., Z. Ram, S. Wallbridge, H. Ishii, E.H. Oldfield, and R.M. Blaese. 1992. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1550-1552.
36. Di Maio, J.M., B.M. Clary, D.F. Via, E. Coveney, T.N. Pappas, and H.K. Lyerly. 1994. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 116:205-213.
37. Kaneko, S., P. Hallenbeck, T. Kotani, H. Nakabayashi, G. McGarrity, T. Tamaoki, W.F. Anderson, and Y.L. Chiang. 1995. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55:5283-5287.
38. Link, C.J., Jr., E.M. Kolb, and R.R. Muldoon. 1995. Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma. 14:143-147.
39. Smythe, W.R., H.C. Hwang, K.M. Amin, S.L. Eck, B.L. Davidson, J.M. Wilson, L.R. Kaiser, and S.M. Albelda. 1994. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 54:2055-2059.
40. Tanaka, T., F. Kanai, S. Okabe, Y. Yoshida, H. Wakimoto, H. Hamada, Y. Shiratori, K. Lan, M. Ishitobi, and M. Omata. 1996. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 56:1341-1345.
41. Huber, B.E., E.A. Austin, C.A. Richards, S.T. Davis, and S.S. Good. 1994. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA. 91:8302-8306.
42. Mullen, C.A., M.M. Coale, R. Lowe, and R.M. Blaese. 1994. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54:1503-1506.
43. Mullen, C.A., M. Kilstrup, and R.M. Blaese. 1992. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA. 89:33-37.
44. Manome, Y., P.Y. Wen, Y. Dong, T. Tanaka, B.S. Mitchell, D.W. Kufe, and H.A. Fine. 1996. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2:567-573.
45. Green, N.K., D.J. Youngs, J.P. Neoptolemos, F. Friedlos, R.J. Knox, C.J. Springer, G.M. Anlezark, N.P. Michael, R.G. Melton, M.J. Ford, et al. 1997. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4:229-238.
46. Marais, R., R.A. Spooner, Y. Light, J. Martin, and C.J. Springer. 1996. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56:4735-4742.